Linagliptin Stada (Linagliptin)

Linagliptin is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus. It helps achieve better glycaemic control when used as part of a comprehensive treatment plan.

• Type 2 diabetes mellitus: improves glycaemic control in adults when combined with diet and exercise.

• Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which results in increased circulating levels of the incretin hormones GLP‑1 and GIP. Higher incretin concentrations enhance glucose‑dependent insulin secretion and suppress glucagon release, thereby lowering post‑prandial and fasting blood glucose levels without causing insulin release at normal glucose concentrations.

Common side effects are generally mild and may resolve without intervention.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient head discomfort.
• Dizziness: occasional light‑headed sensation.
• Gastrointestinal upset: includes nausea or abdominal discomfort.
• Upper respiratory tract infection: mild cold‑like symptoms.
• Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate medical attention.
• Severe allergic reactions: such as angioedema or anaphylaxis.
• Hepatic injury: elevated liver enzymes or jaundice.
• Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.
• Bullous pemphigoid: rare skin blistering disorder.
• Stevens‑Johnson syndrome: serious skin reaction.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential adverse events.

• Renal impairment: assess kidney function and adjust therapy as needed.
• Hepatic impairment: monitor liver enzymes regularly.
• Pregnancy: safety not established; avoid unless benefits outweigh risks.
• Elderly patients: watch for hypoglycaemia when used with other glucose‑lowering agents.
• Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Linagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Insulin or sulfonylureas: may cause severe hypoglycaemia.
• Strong P‑gp inhibitors (e.g., itraconazole): can increase linagliptin exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely)

• Rifampin: may reduce linagliptin effectiveness.
• Diuretics: monitor renal function and electrolytes.
• ACE inhibitors: watch blood pressure and renal parameters.